Health sector in Valencia: focus of international investment.

4/04/2022 VALÈNCIA – (ValenciaPlaza). Valencia is the city of wellness and health, awarded as the healthiest city in the world to live in 2021 and 2022. In recent years it has consolidated a powerful ecosystem of companies in the biotechnology and health sector, contributing a turnover of 1,100 million euros and employing 7,800 people. For this reason, national and international investors and companies choose it as a center for the development of their business activities. When consulting the annual history of business investments, it is common to find a purchase or entry through participation in Valencian companies.
Spain is one of the largest markets in in-vitro fertilization. In Valencia, the Instituto Valenciano de Infertilidad (IVI), a global leader in the area of fertility and reproduction, stands out. Recently, 80% of its shares were bought by the US fund KKR for 3 billion euros, making it one of the most important private equity investments in Spain this year.
Similarly, IVI’s owners had already carried out a similar operation in 2019, selling the company Igenomix to the Swedish investment fund EQT for €1.25 billion.
Another area that stands out in the healthcare sector is genetics. In particular, the Institute of Genomic Medicine (known as Imegen) – one of the Valencian biotech companies with the highest turnover and a benchmark for its cutting-edge contributions in health. In 2017 it was sold to the investment funds Q-Growth Fund and Biolt, who would later merge with Genycell Biotech and Health in Code, creating a powerful business group.
In it, we can find companies such as Polypeptide Therapeutic Solutions (PTS), a company that works with the release of active ingredients in the area of oncology and neurodegenerative diseases. In 2021, PTS was acquired by Arcline, a powerful private equity fund.
As València is positioned as an important hub for innovative technology-based companies, we found a high level of interest from international and national investors – who are actively participating in several financing rounds. An example of this interest can be seen in companies such as Highlight Therapeutics, which obtained financing of 22.6 million euros, or Quibim (8 million euros). Investors include large international firms and funds such as Advent Life Science, Angels and Amadeus Capital Partners.